Tumor Suppressor Protein p53
"Tumor Suppressor Protein p53" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Descriptor ID |
D016159
|
MeSH Number(s) |
D12.776.157.687.650 D12.776.260.820 D12.776.624.776.775 D12.776.660.720.650 D12.776.744.845
|
Concept/Terms |
Tumor Suppressor Protein p53- Tumor Suppressor Protein p53
- p53 Antigen
- TP53 Protein
- TRP53 Protein
- p53 Tumor Suppressor Protein
- pp53 Phosphoprotein
- Phosphoprotein, pp53
- Cellular Tumor Antigen p53
- Oncoprotein p53
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Protein p53".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Protein p53".
This graph shows the total number of publications written about "Tumor Suppressor Protein p53" by people in this website by year, and whether "Tumor Suppressor Protein p53" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 11 | 6 | 17 |
1995 | 27 | 7 | 34 |
1996 | 23 | 11 | 34 |
1997 | 19 | 13 | 32 |
1998 | 30 | 35 | 65 |
1999 | 26 | 15 | 41 |
2000 | 31 | 21 | 52 |
2001 | 24 | 16 | 40 |
2002 | 25 | 20 | 45 |
2003 | 42 | 37 | 79 |
2004 | 30 | 26 | 56 |
2005 | 28 | 24 | 52 |
2006 | 34 | 29 | 63 |
2007 | 41 | 28 | 69 |
2008 | 28 | 20 | 48 |
2009 | 38 | 29 | 67 |
2010 | 39 | 31 | 70 |
2011 | 54 | 43 | 97 |
2012 | 36 | 32 | 68 |
2013 | 41 | 32 | 73 |
2014 | 41 | 32 | 73 |
2015 | 32 | 33 | 65 |
2016 | 38 | 32 | 70 |
2017 | 35 | 19 | 54 |
2018 | 34 | 21 | 55 |
2019 | 30 | 27 | 57 |
2020 | 23 | 30 | 53 |
2021 | 26 | 13 | 39 |
2022 | 10 | 30 | 40 |
2023 | 10 | 23 | 33 |
2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Protein p53" by people in Profiles.
-
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Sci Transl Med. 2024 Feb 14; 16(734):eadj5962.
-
Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. Sci Adv. 2024 Feb 16; 10(7):eadk1835.
-
LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations. JCO Clin Cancer Inform. 2024 Feb; 8:e2300167.
-
FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner. Clin Cancer Res. 2024 01 05; 30(1):187-197.
-
Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun. 2024 Jan 02; 15(1):180.
-
p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis. Cancer Res Commun. 2023 12 29; 3(12):2640-2652.
-
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action. Cancer Treat Rev. 2024 Jan; 122:102668.
-
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes. Clin Cancer Res. 2023 12 01; 29(23):4844-4852.
-
Competing Engagement of ?-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness. Mol Cancer Res. 2023 12 01; 21(12):1288-1302.
-
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023 12; 9(48):eadh1436.